Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP733989.RAIrPYCF4y55AqHhTyFdh079eXrZxYw-O1ll6y_mrDU2U130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP733989.RAIrPYCF4y55AqHhTyFdh079eXrZxYw-O1ll6y_mrDU2U130_assertion type Assertion NP733989.RAIrPYCF4y55AqHhTyFdh079eXrZxYw-O1ll6y_mrDU2U130_head.
- NP733989.RAIrPYCF4y55AqHhTyFdh079eXrZxYw-O1ll6y_mrDU2U130_assertion description "[When WT1 Ab was combined with CEA or CYFRA for detection of NSCLC, positive detection rates increased from 25.0 to 34.1 and 31.8%, respectively, in stage I and from 38.4 to 69.2 and 46.1%, respectively, in stage III, but not changed in stage II.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP733989.RAIrPYCF4y55AqHhTyFdh079eXrZxYw-O1ll6y_mrDU2U130_provenance.
- NP733989.RAIrPYCF4y55AqHhTyFdh079eXrZxYw-O1ll6y_mrDU2U130_assertion evidence source_evidence_literature NP733989.RAIrPYCF4y55AqHhTyFdh079eXrZxYw-O1ll6y_mrDU2U130_provenance.
- NP733989.RAIrPYCF4y55AqHhTyFdh079eXrZxYw-O1ll6y_mrDU2U130_assertion SIO_000772 19384943 NP733989.RAIrPYCF4y55AqHhTyFdh079eXrZxYw-O1ll6y_mrDU2U130_provenance.
- NP733989.RAIrPYCF4y55AqHhTyFdh079eXrZxYw-O1ll6y_mrDU2U130_assertion wasDerivedFrom befree-2016 NP733989.RAIrPYCF4y55AqHhTyFdh079eXrZxYw-O1ll6y_mrDU2U130_provenance.
- NP733989.RAIrPYCF4y55AqHhTyFdh079eXrZxYw-O1ll6y_mrDU2U130_assertion wasGeneratedBy ECO_0000203 NP733989.RAIrPYCF4y55AqHhTyFdh079eXrZxYw-O1ll6y_mrDU2U130_provenance.